Reversing fibrosis remains a significant challenge. However, early detection and intervention can halt or slow its progression. Current research is focused on identifying antifibrotic agents that can disrupt the fibrotic process. Agents targeting TGF-beta signaling, a key pathway in fibrosis, are showing promise in preclinical and clinical studies.
